On Monday, Moderna (MRNA) provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At the conference, the company lowered its previously issued sales outlook for 2024 and 2025.Moderna reported unaudited/preliminary product sales between $3 billion and $3.1 billion for 2024, toward the lower end of its previously issued guidance of $3.0-$3.5 billion. MRNA also reduced its previously announced sales guidance for 2025 by $1 billion and now expects total revenu ...

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (MRNA -2.30%). The company, which was a leader in developing one of the initial COVID-19 vaccines, has plunged by 20% for the week as of mid-day Thursday.Disappointing sales guidance is the key reason for the plungeThe main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin. The prior forecast called for $2.5 billion to $3.5 bi ...

Moderna (MRNA 0.90%) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. This helped the stock to skyrocket, reaching a high of more than $480 at its peak in 2021.Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial virus (RSV) vaccine mRESVIA -- hasn't ...

Moderna (MRNA 0.90%) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long.Since reaching a peak last May, Moderna stock has tumbled by about 79%, and investors are starting to wonder if it could be a bargain now.Here's a look at what's been pressuring the formerly high-flying biotech stock to see if it can bounce back from the severe beating it's received over the past several months.Why Moderna Stock is getting hammeredOn Jan. 13, ...

A bad seven-month stretch just got worse for Moderna (MRNA -1.96%). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday. This update wasn't well-received by investors, and Moderna's share price sank nearly 17%.The conventional investing wisdom is that you shouldn't "try to catch a falling knife." Moderna's stock chart certainly looks like a falling knife. Even before the latest decline, the biotech stock was down roughly 73% since early ...

At the J.P. Morgan Healthcare Conference, Moderna (MRNA) announced several financial updates on its business and updates on its pipeline progress.Moderna’s Financial Updates Fail to Impress InvestorsFor 2024Moderna reported unaudited/preliminary product sales between $3 billion and $3.1 billion for 2024. This includes more than $3 billion in COVID-19 vaccine sales and minimal sales from the RSV vaccine mResvia. This figure was mainly toward the lower end of the company’s previously issued guidance of $3.0-$ ...

Key TakeawaysModerna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two-month pennant pattern, setting the stage for a potential continuation move lower.Investors should watch crucial support levels on Moderna's chart around $30 and $13, while also monitoring key resistance levels near $57 and $68. Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plungin ...

Key TakeawaysThe S&P 500 ended 0.2% higher on Monday, Jan. 13, 2025, ahead of this week's inflation data and the first wave of earnings reports from the nation's biggest banks.Moderna shares plummeted after the biotech firm slashed its 2025 revenue guidance, citing uncertain vaccine demand.Shares of managed care companies moved higher following the U.S. government's proposal to raise Medicare Advantage reimbursement rates next year. Major U.S. equities indexes were mixed to start a new trading week ahead of ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - Shares of pharmaceutical giant Moderna (MRNA) experienced a significant decline after the company revised its 2025 revenue forecast downward by $1 billion [1][4]. Revenue Forecast - Moderna now projects its revenue for the current year to be between $1.5 billion and $2.5 billion, a decrease from the previous estimate of $2.5 billion to $3.5 billion made in September [2]. - The company anticipates that most of this revenue will be generated in the second half of the year, primarily from sales of its Covid-19 and respiratory syncytial virus (RSV) vaccines [2][4]. Expense Management - Moderna plans to implement a $1 billion reduction in expenses for the current year, with an additional $500 million cut expected in 2026 [2]. Stock Performance - The stock price of Moderna fell over 20% intraday to $33.44, effectively negating gains made the previous week following the first reported bird-flu death in the U.S. [3]. - Over the past year, Moderna's stock has lost approximately two-thirds of its value and is significantly below its all-time high of nearly $490 reached in August 2021 during the COVID-19 pandemic [3][4].